GW Pharmaceuticals PLC-ADR GWPH has risen to $91.57 since its previous Vetr rating of 2.5 stars was issued two days ago. On Friday, the Vetr community upgraded their rating to three stars.
The British pharmaceutical company rallied on Tuesday on the release of positive data from their drug Epidiolex.
Overall though, sentiment on Vetr is bearish. Less than 2 percent of Vetr users are holding it in their watch-lists, and 57 percent of the crowd's ratings are bearish. The Vetr crowd sees a price target of $89.66, compared to analyst projections $131.25.
See how Vetr's crowdsourced ratings can help you beat the market.
At time of writing, GW Pharma was up 1.64 percent at $93.07.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
